

Empower Change: Workload management of nurses caring for people with **multiple sclerosis**



127 nurses from 21 countries completed the survey.

The average completion time was 11 minutes, representing over 23 hours of data input.

• 59% (n=75/127) of respondents have a caseload >300 PwMS per year, who they see ≥ 2 times/year, spending between 30 minutes and 3 hours including consultation and follow-up tasks at each visit.

Average nurse caseload of individual PwMS per year

(one patient = 1 caseload, irrespective of number of consultations) (n=127)



 Work left unfinished due to time constraints includes clinical trials, social benefits advice, diagnostic procedures and paperwork completion. Over half of nurses surveyed have no or limited administrative support.

Work left undone

(%, nurses were asked to score each task where 1 = no type of this work is left undone and 10 = a lot of this type of work is left undone)



Background

MS Nurse PROfessional is an educational programme and community to train and support nurses caring for people with MS (PwMS). With over 1000 active members across Europe, it serves as a platform to increase knowledge, enhance skills and share expertise.



Aims and objectives

As part of advocating for improved working conditions, MS Nurse PROfessional conducted a survey to understand current workload practices of neuroscience nurses in Europe that care for PwMS, and their opinions on potential solutions to address unfinished tasks.



Methods

Developed by the Steering and Syllabus Committee of MS Nurse PROfessional, the online survey included questions about demographics, professional background and workload management when caring for PwMS. Questions were reviewed by board members from Rehabilitation in Multiple Sclerosis (RIMS) and piloted by 6 nurses from our community, with the survey available in 10 languages. MS Nurse PROfessional community members were invited to participate. The survey ran from February 1, 2024 to June 30, 2024. Final results and findings are reported here.

 Nurses (n=127) dedicate the majority of their time to symptom management, completion of necessary paperwork, treatment selection/ monitoring and educating the PwMS and their family.

Nurses (%)

% of working time assigned to tasks

Task	0-5%	5-15%	16 - >25%
Treatment selection/monitoring, management of side effects	16%	24%	61%
Symptom management	9%	29%	62%
Educating the PwMS, and family/general counselling	19%	29%	52%
Completing necessary paperwork (electronic patient files, etc)	13%	25%	61%
Diagnostic procedures (e.g. blood drawing, clinical or technical test procedures)	33%	17%	50%

Nurses (%)

• The findings indicate that the nursing community is advocating for an increase in the number of nurse colleagues (57%), increased access to psychological support for the PwMS (54%), and the ability for nurses to refer to a multidisciplinary care team (52,8%).

Priority of potential solutions

(%, nurses were asked to score each task where 1 = not a priority and 10 = highest priority)



Nurses (%)

80%

4-7



Conclusions

This survey of nurses caring for PwMS shows the specialised tasks nurses perform in symptom management, treatment monitoring and educating the PwMS.

The survey also confirms that a caseload of in excess of 300 PwMS is common among MS Nurses.

Conclusions that can be drawn from the survey suggest that increasing the number of nurse colleagues, increasing the availability of administrative support and access to psychological support for PwMS and increasing the ability to refer to a multidisciplinary care team can all contribute to enabling MS Nurses to focus on their specialised and essential tasks to support the wellbeing of all PwMS in their care.



Let's shape the future of MS nursing together!

Scan the QR code to stay up to date on our work on this important topic.



Authors: Piet Eelen*1, Wolfgang Kohler², Amy Perrin Ross³, Miguel Angel Robles Sanchez⁴, Megan Roberts⁵, Roberta Motta⁶, Anne Rahn⁷, Zoe Wahl⁸, Zeliha Tulek³, Shana Pezaro¹⁰, Lousin Moumdjian¹¹, Elena Kelly¹², Stefaan De Corte

1. National MS Center Melsbroek, Belgium; 2. University of Leipzig Medical Center, Germany; 3. Loyola University Medical Center, United States; 4. Centre d'Esclerosi Múltiple de Catalunya, Spain; 5. MS Trust UK, United Kingdom; 6. Italian MS Society, Italy; 7. Universität zu Lübeck, Germany; 8. Hôpitaux Universitaries de Genève, Switzerland; 9. University of Istanbul, Turkey; 10. Patient representative UK; 11. University of Hasselt, Belgium; 12. European Multiple Sclerosis Platform, Belgium.

Corresponding author: n De Corte, msnursepro@emsp.ord

Disclosures

Funders of MS Nurse PROfessional that supported this research are AMGEN, Biogen, BMS, Coloplast, Merck, Novartis Roche, Sandoz and Viatris.

Piet Eelen has received grant support, consulting fees and served as an expert on advisory boards for Bioger Coloplast, ConvaTec, EG, Merck, Novartis, Roche, Sandoz and Viatris.

Wolfgang Kohler has received grants or contracts from Bluebird Bio, Minoryx Therapeutics, and SwanBio Therapeutics; consulting fees from Alexion, Bristol Myers Squibb, Minoryx Therapeutics, Poxel, Pharmaelle, Roche, and Vigil; honoraria or travel support from Bayer, Biogen, and Minoryx Therapeutics. Wolfgang Köhler serves on scientific advisory boards of the United Leukodystrophy Foundation, the European Leukodystrophy Association, the Myelin Project Germany, and the German Multiple Sklerose Gesellschaft. Wolfgang Köhler receives institutional research funds by a German Ministry of Health grant "LeukoExpert" (2520DAT94B) and EU grant "Tackle Genetic White Matter Diseases", supported by tax funds on the basis of the budget adopted by the Saxon state parliament.

Amy Perrin Ross has received consulting fee from EMD Serono, BMS, Horizon, Alexion, TG Therapeutics, Novartis, Roche, and Sanofi.

Zeliha Tulek: nothing to disclose

Elena Kelly: nothing to disclose.

Lousin Moumdjian: nothing to disclose

Stefaan De Corte: nothing to disclose

MA Robles-Sanchez received speaking or consulting honoraria, participated in scientific activities organized by Merck, Teva, Biogen, Novartis, Sanofi-Genzyme, Celgene, EXCEMED, Jansenn, BM, Sandoz and Roche; was awarded by the ECTRIMS MS Nurse Training Fellowship 2015 and the International Organization of Multiple Sclerosis Nurses (IOMSN) – International Nightingale Awards 2022; and received grants from the Programme and the Strategic Plan for Research and Innovation in Health 2016-2020 (PERIS) (ref. SLT017/20/000193) and the Official College of Nurses of Barcelona as part of the Nurse Research Projects Grants (PRN-475/2021).

Megan Roberts has received consulting fees from Kiniksa.

Anne Rahn: nothing to disclose. Zoe Wahl: nothing to disclose. Roberta Motta: nothing to disclose. ana Pezano: nothing to disclose

EUROPEAN

MULTIPLE SCLEROSIS PLATFORM